Malnutrition-inflammation-atherosclerosis (MIA syndrome) in patients with renal failure;Zespół niedożywienie-zapalenie-miażdżyca (zespół MIA) u chorych z niewydolnościa̧ nerek

Polski Merkuriusz Lekarski

Volumn 15, Issue 88, 2003, Pages 334-343

  Pawlaczyk, Krzysztof ^a,c   Oko, Andrzej ^a   Lindholm, Bengt ^b   Czekalski, Stanisław ^a,d   Januszewicz, Włodzimierz ^d   Myśliwiec, Michał ^d   Manitius, Jacek ^d   Nartowicz, Edmund ^d   Chrzanowski, Witold ^d   Hruby, Zbigniew ^d   Pupek Musialik, Danuta ^d   Lao, Mieczysław ^d  

^a Katedra i Klinika Nefrologii   (Poland)

^b KAROLINSKA INSTITUTE   (Sweden)

^c Katedra i Klinika Dermatologii   (Poland)

^d NONE

Author keywords

Atherosclerosis; Chronic renal failure; Inflammation; Malnutrition; MIA syndrome

Indexed keywords

C REACTIVE PROTEIN; CYTOKINE; INTERLEUKIN 6; TUMOR NECROSIS FACTOR ALPHA;

ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CAUSE OF DEATH; CONFERENCE PAPER; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DISEASE EXACERBATION; ENDOTHELIUM CELL; HEART FAILURE; HUMAN; INFECTION SENSITIVITY; INFLAMMATION; KIDNEY FAILURE; MALNUTRITION; MORTALITY; OXIDATIVE STRESS; RISK FACTOR; UREMIA; ARTERIOSCLEROSIS; ARTICLE; CHRONIC KIDNEY FAILURE; METHODOLOGY; PATHOPHYSIOLOGY; PERITONEAL DIALYSIS; SYNDROME;

ARTERIOSCLEROSIS; HUMANS; INFLAMMATION; KIDNEY FAILURE, CHRONIC; MALNUTRITION; PERITONEAL DIALYSIS; SYNDROME;

EID: 0242680440     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (131)

1. Acchiardo S.R. i wsp.: Malnutrition as a main factor in morbidity and mortality of hemodialysis patients. Kidney Int., 1983, 24 (suppl 16), S199.
2. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: Association with clinical outcomes. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. J. Am. Soc. Nephrol., 1996, 7, 198.
3. Aguilera A. i wsp.: Anorexia in end-stage renal disease: Pathophysiology and treatment. Expert Opi. Pharmacother., 2001, 2, 1825.
4. Albert M.A. i wsp.: Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA, 2001, 286, 64.
5. Alexander R.W.: Hypertension and the pathogenesis of atherosclerotic oxidative stress and the mediation of arterial inflammatory response: a new perspective. Hypertension, 1995, 25, 155.
6. Altavilla D. i wsp.: IRFI 042, a novel dual vitamin E-like antioxidant, inhibits activation of nuclear factor-B and reduces the inflammatory response in myocardial ischaemia-reperfusion injury. Cardiovasc. Res., 2000, 47, 515.
7. Anderson K.M. i wsp.: Cardiovascular disease risk profiles. Am. Heart. J., 1991, 121, 293.
8. Annuk M. i wsp.: Impaired endothelium-dependent vasodilation in renal failure in humans. Nephrol. Dial. Transplant., 2001, 16, 302.
9. Ataman P.O. i wsp.: Lipoprotein metabolism and renal failure. Am. J. Kidney Dis., 1993, 21, 573.
10. Avram M.M. i wsp.: Predictors of survival in continuous ambulatory peritoneal dialysis patients: A five year prospective study. Perit. Dial. Int., 1996, 16(suppl 1), S190.
11. Bartens W. i wsp.: Elevated lipoprotein (a) and fibrinogen levels increase the cardiovascular risk in continuous ambulatory peritoneal dialysis patients. Pedt. Dial. Int., 1996, 16, 27.
12. Beharka A.A. i wsp.: Interleukin-6 production does not increase with age. J. Geront., 2001, 56, B81.
13. Bemelmans M.H. i wsp.: Influence of nephrectomy on tumor necrosis factor clearance in murine model. J. Immunol., 1993, 150, 2007.
14. Bergstrom J. i wsp.: Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritone-aldialysis. Kidney Int., 1993, 44, 1048.
15. Bergström J.: Why are dialysis patients malnourished? Am. J. Kidney Dis., 1995, 26, 229.
16. Boaz M. i wsp.: Secondary prevention with antioxidants of cardiovascular disease in endstage renal disease (SPACE): randomised placebo-controlled trial. Lancet, 2000, 356, 1213.
17. Bologa R.M. i wsp.: Interleukin-6 predicts hypoalbuminemia, hypocholesterolemia, and mortality in hemodialysis patients. Am. J. Kidney Dis., 1998, 32, 107.
18. Brull D.J. i wsp.: Interleukin-6 gene -174g>c and -572g>c promotor polymorphisms are strong predictors of plasma interleukin-6 levels after coronary artery bypass surgery. Arterioscler. Thromb. Vasc. Biol., 2001, 21, 1458.
19. Caravaca F. i wsp.: Uraemic symptoms, nutritional status and renal function in predialysis endstage renal failure patients. Nephrol. Dial. Transplant., 2001, 16, 776.
20. Cavaillon J.M. i wsp.: Serum interleukin-6 in long-term hemodialysed patients. Nephron 1992, 60, 307.
21. Celermajor D.S. i wsp.: Cigarette smoking is associated with doserelated and potentially reversible impairment of endothelium-dependent dilation in healthy young adults. Circulation, 1993, 88, 2149.
22. Chang J.W. i wsp.: Effects of simulation on highsensitivity C-reactive protein and serum albumin in hemodialysis patients. Am. J. Kidney Dis., 2002, 39, 1213.
23. Chen Y. i wsp.: Restoration of tight junction structure and barrier function by downregulation of the mitogen-activated protein kinase pathway in rastransformed Madin-Darby canine kidney cells. Mol. Biol. Cell., 2000, 11(3), 849.
24. Chi D. i.wsp: The effects of HIV infection on endothelial function. Endothelium, 2000, 7, 223.
25. Chung S.H. i wsp.: Association between inflammation and changes in residual renal function and peritoneal transport rate during the first year of dialysis. Nephrol. Dial. Transplant., 2001, 16, 2240.
26. Chung S.H. i wsp.: Influence of initial nutritional status on continuous ambulatory peritoneal dialysis patient survival. Perit. Dial. Int., 2000, 20, 19.
27. Cressman M.D. i wsp.: Lipoprotein(a) is an independent risk factor for cardiovascular disease in hemodialysis patients. Circulation. 1992, 86, 475.
28. Descamps-Latscha B. i wsp.: Balance between IL-1, TNF-α, and their specific inhibitors in chronic renal failure and maintenance dialysis. J. Immunol., 1995, 154, 882.
29. Devaraj S., Jialal I.: Alpha tocopherol supplementation decreases serum C-reactive protein and monocyte interleukin-6 levels in normal volunteers and type-2 diabetic patients. Free Radic. Biol. Med., 2000, 29, 790.
30. Espinoza M. i wsp.: Tumour necrosis factor alpha as uremic toxin: correlation with neuropathy, left ventricular hypertrophy, anemia, and hypertriglyceridemia in peritoneal dialysis patients. Adv. Perit. Dial., 1999, 15, 82.
31. Fernandez-Real J.M. i wsp.: Circulating interleukin 6 levels, blood pressure, and insulin sensitivity in apparently healthy men and women. J. Clin. Endocrinol. Metab., 2001, 86, 1154.
32. Fishman D. i wsp.: The effect of novel polymorphisms in the interleukin-6 (IL-6) gene on IL-6 transcription and plasma IL-6 levels, and an association with systemic-onset juvenile chronic arthritis. Circulation, 1998, 102, 1369.
33. Folsom A.R. i wsp.: Low serum albumin. Association with diabetes mellitus and other cardiovascular risk factors but not with prevalent cardiovascular disease or carotid artery intima media-media thickness. Ann. Epidemiol., 1995, 5, 186.
34. Fukuzawa M. i wsp.: Angiotensin-converting enzyme inhibitors suppress production of tumor necrosis factor-alpha in vitro and in vivo. Immunopharmacology, 1997, 36, 49.
35. Garg A.X. i wsp.: Association between renal insufficiency and malnutrition in older adults: Results from the NHANES III. Kidney Int., 2001, 60, 1867.
36. Ghiadoni L. i wsp.: Mental stress induces transient endothelial dysfunction in humans. Circulation, 2000, 102, 2473.
37. Gullestad L. i wsp.: Effect of high-versus low-dose angiotensin converting enzyme inhibition on cytokine levels in chronic heart failure. J. Am. Coll. Cardiol., 1999, 34, 2061.
38. Hak A.E. i wsp.: Markers of inflammation and cellular adhesion molecules in relation to insulin resistance in nondiabetic elderly: the Rotterdam study. J. Clin. Endocrinol. Me-tab., 2001, 86, 4398.
39. Harris T.B. i wsp.: Association of elevated interleukin-6 and C-reactive protein levels with mortality in the elderly. Am. J. Med., 1999, 106, 506.
40. Haubitz M., Brunkhorst R.: C-reactive protein and chronic Chlamydia pneumoniae in-fection-long term predictors for cardiovascular disease and survival in patients on peri-toneal dialysis. Nephrol. Dial. Transplant., 2001, 16, 809.
41. Heberlin A. i wsp.: Elevated circulating levels of interleukin-6 in patients with chronic renal failure. Kidney Int., 1991, 39, 954.
42. Heimburger O. i wsp.: Handgrip muscle strength, lean body mass, and plasma proteins as markers of nutritional status in patients with chronic renal failure close to start of dialysis therapy. Am. J. Kidney Dis., 2000, 36, 1213.
43. Heinrich J. i wsp.: Association of variables of coagulation, fibrinolysis and acute-phase with atherosclerosis in coronary and peripheral arteries and those arteries supplying the brain. Thromb. Haemost., 1995, 73, 374.
44. Hurst S.M., i wsp.: IL-6 and its soluble receptor orchestrate a temporal switch in the pattern of leucocyte recruitment seen during acute inflammation. Immunity, 2001, 14, 705.
45. Iiyyama K. i wsp.: Impaired endothelial function with essential hypertension assessed by ultrasonography. Am. Heart J., 1996, 132, 779.
46. Jansen M.A.M. i wsp.: Renal function and nutritional status at the start of chronic dialysis treatment. J. Am. Soc. Nephrol., 2001, 12, 157.
47. Joki N. i wsp.: Progression of coronary atherosclerosis is accelerated in hemodialysed (HD) patients than chronic renal insufficiency (CRI) patients (abstract). Nephrol. Dial. Transplant., 1999, 14, 222,
48. Kaizu Y. i wsp.: Interleukin-6 may mediate malnutrition in chronic hemodialysis patients. Am. J. Kidney. Dis., 1998, 31, 93.
49. Kaysen G.A.: Biological basis of hypoalbuminemia in ESRD. Kidney Int., 1998, 9, 2368.
50. Kaysen G.A. i wsp.: The acutephase response varies with time and predicts serum albumin levels in hemodialysis patients. Kidney Int., 2000, 58, 346.
51. Kaysen G.A., Stevenson F.T., Depner T.A.: Determinants of albumin concentration in hemodialysis patients. Am. J. Kidney Dis., 1997, 29, 658.
52. Kern P.A. i wsp.: Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am. J. Physiol., 2001, 280, E745.
53. Kessler P. i wsp.: Proinflammatory mediators chronically downregulate the formation of the endothelium-derived hyperpolarizing factor in arteries via a nitric oxide/cyclic GMP-dependent mechanism. Circulation, 1999, 99, 1878.
54. Kielstein J.T. i wsp.: Asymetric dimethylarginine plasma concentrations differ in patients with endstage renal disease: Relationship to treatment method and atherosclerotic disease. J. Am. Soc. Nephrol., 1999, 10, 594.
55. Kimmel P.L. i wsp.: Immunologic function and survival in hemodialysis patients. Kid-ney Int., 1998, 54, 236.
56. Koch M. i wsp.: Apolipoprotein A, fibrinogen, age, and a history of stroke are predictors of death in dialyzed diabetic patients: A prospective study in 412 subjects. Nephrol. Dial. Transplant., 1997, 12, 2603.
57. Kopple J. i wsp.: Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int., 1995, 47, 1148.
58. Kopple J.D. i wsp.: Relationship between nutritional status and the glomerular filtration rate: Results from the MDRD study. Kidney Int., 2000, 57, 1688.
59. Kuhlmann M.K., Schmidt F., Kohler H.: High protein/energy vs. standard pro-tein/energy nutritional regimen in the treatment of malnourished hemodialysis patients. Miner. Electrolyte. Metab., 1999, 25, 306.
60. Kuo C., Campbell L.A.: Is infection with Chlamydia pneumoniae a causative agent in atherosclerosis? Mol. Med. Today, 1998, 4, 426.
61. Laws R.A., Tapsell L.C., Kelly J.: Nutritional status and its relationship to quality of life in a sample of chronic dialysis patients. J. Ren. Nutr., 2000, 10, 139.
62. Levine B. i wsp.: Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N. Engl. J. Med., 1990, 323, 236.
63. Lowrie E.G., Lew N.L.: Death risk in hemodialysis patients: The predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am. J. Kidney Dis., 1990, 15, 458.
64. Mack W.J. i wsp.: Lipoprotein subclasses in the Monitored Atherosclerosis Regression Study (MARS). Treatment effects and relation to coronary angiographic progression. Arteioscler. Thromb. Vasc. Biol., 1996, 16, 697.
65. Mallamaci F. i wsp.: Hyperhomocysteinemia predicts cardiovascular outcomes in hemodialysis patients. Kidney Int., 2002, 61, 609.
66. Manzi S. i wsp.: Agespecific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with Framingham study. Am. J. Epidemiol., 1997, 145, 408.
67. Memoli B. i wsp.: Role of different dialysis membranes in the release of interleukin-6 soluble receptor in uremic patients. Kidney Int., 2000, 58, 417.
68. Mendall M.A. i wsp.: C-reactive protein and its relation to cardiovascular risk factors: a population based cross sectional study. BMJ, 1996, 312, 1061.
69. Miyazaki H. i wsp.: Hemodialysis impairs endothelial function via oxidative stress. Effects of vitamin E-coated dialyzer. Circulation, 2000, 101, 1002.
70. Moustapha A. i wsp.: Prospective study of hyperhomocysteinemia as an adverse cardiovascular risk factor in endstage renal disease. Circulation, 1998, 97, 138.
71. Munger M.A. i wsp.: Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am. J. Cardiol., 1996, 77, 723.
72. Münzel T., Keaney J.F.: Are ACE inhibitors a magic bullet against oxidative stress? Circulation, 2001, 104, 1571.
73. Nakanishi I. i wsp.: Interleukin-8 in chronic renal failure and dialysis patients. Nephrol. Dial. Transplant., 1994, 9, 1435.
74. Nascimento M. i wsp.: Inflammation, Malnutrition and Atherosclerosis in End-Stage Renal Disease: A Global Perspective. Blood Purification, 2002, 20, 454.
75. O'Sullivan A.J. i wsp.: Body composition and energy metabolism in chronic renal insufficiency. Am. J. Kidney Dis., 2002, 39, 369, (abstract).
76. Panichi V. i wsp.: C-reactive protein in patients with chronic renal diseases. Renal Fail-ure, 2001, 23, 551.
77. Panichi V. i wsp.: Plasma C-reactive protein in hemodialysis patients: a cross-sectional and longitudinal survey Blood Purification, 2000, 18, 30.
78. Paolisso G. i wsp.: Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic non-insulin dependent diabetic patients. Atherosclerosis, 2000, 150, 121.
79. Parfrey P.S. i wsp.: Outcome and risk factors for left ventricular disorders in chronic uremia. Nephrol. Dial. Transplant., 1996, 11, 1277.
80. Pasceri V., Willerson J.T., Yeh E.T.: Direct proinflammatory effect of C-reactive pro-tein on human endothelial cells. Circulation, 2000, 102, 2165.
81. Pereira B.J.G. i wsp.: Plasma levels of IL-1β, TNF-α and their specific inhibitors in undialyzed chronic renal failure, CAPD and hemodialysis patients. Kidney Int., 1994, 45, 890.
82. Poole S. i wsp.: Fate of injected interleukin 1 in rats: sequestration and degradation in the kidney. Cytokine, 1990, 2, 416.
83. Prasad A. i wsp.: Relation between infections and endothelial dysfunction (abstract). Circulation, 2000, 102 [Suppl. II], 245.
84. Qureshi A.R. i wsp.: Factors predicting malnutrition in hemodialysis patients: A crosssectional study. Kidney Int., 1998, 53, 773.
85. Qureshi A.R. i wsp.: Inflammation, malnutrition and cardiac disease as predictors of mortality in hemodialysis patients. J. Am. Soc. Nephrol., 2002, 13, Suppl. 1, S28.
86. Qureshi A.R.: Malnutrition In patients with chronic renal failure, rozprawa doktorska, Stockholm, Szwecja 2000.
87. Ravussin E. i wsp.: Reduced rate of energy expenditure as a risk factor for bodyweight gain. N. Engl. J. Med., 1988, 318, 467.
88. Ridker P.M., Rifai N., Lowenthal S.P.: Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation, 2001, 103, 1191.
89. Ridker P.M. i wsp.: Plasma concentration of interleukin-6 and the risk of future myocar-dial infarction among apparently healthy men. Circulation. 2000, 101, 1767.
90. Schalkwijk C.G. i wsp.: Plasma concentration of C-reactive protein is increased in Type 1 diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic infection. Diabetologia, 1999, 42, 351.
91. Schindler R., i wsp.: Effect of the hemodialysis membrane on the inflammatory reaction in vivo. Clin. Nephrol., 2000, 53, 452.
92. Schindler R., Dinarello C.A., Koch K.M.: Angiotensin- converting enzyme inhibitors suppress synthesis of tumor necrosis factor and interleukin 1 by human peripheral blood mononuclear cells. Cytokine, 1995, 7, 526.
93. Schouten W.E.M., i wsp.: Effects of dialyser and dialysate on the acute phase response in clinical bicarbonate dialysis. Nephrol. Dial. Transplant., 2000, 15, 379.
94. Seliger S.I. i wsp.: HMG-CoA reductase inhibitors are associated with reduced mortality in ESRD patients. Kidney Int., 2002, 61, 297.
95. Shoji T. i wsp.: Intermediate density lipoproteins as an independent risk factor for aortic atherosclerosis In hemodialysis patients, J. Am. Soc. Nephrol., 1998, 9, 1277.
96. Smith D,A. i wsp.: Serum levels of the antiinflammatory cytokine interleukin-10 are decreased in patients with unstable angina. Circulation, 2001, 104, 746.
97. Smith E.B., Thompson W.D.: Fibrin as a factor in atherogenesis. Thromb. Res., 1994, 73, 1.
98. Smith G., Robinsson P.H., Fleck A.: Serum albumin distribution in early treated anorexia nervosa. Nutrition, 1996, 12, 677.
99. Sorensen K.E. i wsp.: Impairment of endothelium-dependent dilation is an early event in children with familial hypercholesterolemia and is related to lipoprotein(a) level. J. Clin. Invest., 1994, 93, 50.
100. Spittle M. i wsp.: Relationship between antibodies to periodontal pathogens and C-reactive protein (CRP) levels in hemodialysis patients. J. Am. Soc. Nephrol., 2000, 11, 299A.
101. Stenvinkel P. i wsp.: Do ACE-inhibitors suppress tumor necrosis factor-production in advanced chronic renal failure? J. Intern. Med., 1999, 246, 503.
102. Stenvinkel P. i wsp.: Does persistent infection with Chlamydia pneumoniae increase the risk of atherosclerosis in chronic renal failure? Kidney Int., 1999, 55, 2531.
103. Stenvinkel P. i wsp.: Are there two types of malnutrition in chronic renal failure? Evi-dence for relationships between malnutrition, inflammation and atherosclerosis (MIA-syndrome). Nephrol. Dial., Transplant., 2000, 15, 953.
104. Stenvinkel P. i wsp.: Strong associations between malnutrition, inflammation and atherosclerosis in chronic renal failure. Kidney Int., 1999, 55, 1899.
105. Stenvinkel P. i wsp.: Apo(a) isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int., 1998, 53, 1336.
106. Stenvinkel P. i wsp.: Elevated serum levels of soluble adhesion molecules predicts death in predialysis patients: associations with malnutrition, inflammation and cardiovascular disease. Nephrol. Dial. Transplant., 2000, 15, 1624.
107. Stenvinkel P. i wsp.: Inflammation and outcome in end-stage renal failure: does female gender constitute a survival advantage? Kidney Int., 2002, 62(5), 1791.
108. Stenvinkel P. i wsp.: Mortality, malnutrition, and atherosclerosis in ESRD: What is the role of interleukin-6? Kidney Int., 2002, Suppl. 80, S103.
109. Stenvinkel P. i wsp.: Are there two types of malnutrition in chronic renal failure? Evi-dence for relationships between malnutrition, inflammation and atherosclerosis (MIA syndrome). Nephrol. Dial. Transplant., 2000, 15(7), 953.
110. Stenvinkel P.: Inflammatory and Atherosclerotic Interactions in the Depleted Uremic Patent. Blood Pudf., 2001, 19, 53.
111. Stenvinkel P.: Malnutrition and chronic inflammation as risk factors for cardiovascular disease in chronic renal failure. Blood Purif., 2001, 19, 143.
112. Struijk D.G. i wsp.: The effect of serum albumin at the start of continuous ambulatory peritoneal dialysis treatment on patient survival. Perit. Dial. Int., 1994, 14, 121.
113. Tielemans C i wsp.: Effects of ultrapure and nonsterile dialysate on the inflammatory response during in vitro hemodialysis. Kidney Int., 1996, 49, 236.
114. Togashi N. i wsp.: The contribution of skeletal muscle tumor necrosis factor-alpha to insulin resistance and hypertension in fructosefed rats. J. Hypertens., 2000, 18, 160.5
115. Torzewski J. i wsp.: C-reactive protein frequently colocalizes with the terminal com-plement complex in the intima of early atherosclerotic lesions of human coronary arteries. Arterioscler. Tromb. Vasc. Biol., 1998, 18, 1386.
116. Uppritchard J.E., Sutherland W.H.F., Mann J.I.: Effect of supplementation with tomato juice, vitamin E, and vitamin C on LDL oxidation and products of inflammatory activity in type 2 diabetes. Diabetes Care, 2000, 23, 733.
117. Vallance P. i wsp.: Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet, 1992, 339, 572.
118. Van Lenten B.J. i wsp.: Antiinflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J. Clin. Invest., 1995, 96(6), 2758.
119. van Riemsdijk-van Overbeeke I.C. i wsp.: TNF-α mRNA, plasma protein levels and soluble receptors in patients with chronic hemodialysis, on CAPD and with endstage renal failure. Clin. Nephrol., 2000, 53, 115.
120. Vanholder R. i wsp.: Uremic toxicity: present state of the art. Int. J. Artif. Organs, 2001, 24, 695.
121. Visser M. i wsp.: Elevated C-reactive protein levels in overweight and obese adults. JAMA, 1999, 282, 2131.
122. Volpatd S. i wsp.: Cardiovascular disease, interleukin-6, and risk of mortality in older women: the woman health and aging study. Circulation, 2001, 103, 947.
123. Wieser R.J. i wsp.: Isolation and characterization of a 60-70-kD plasma membrane glycoprotein involved in the contact-dependent inhibition of growth. J. Cell. Biol., 1990, 111(6 Pt 1), 2681.
124. Yeh S.S., Schuster M.W.: Geriatric cachexia: The role of cytokines. Am. J. Clin. Nutr., 1999, 70, 183.
125. Yeun J.Y., Kaysen G.A.: Acute phase proteins and peritoneal dialysate albumin loss are the main determinants of serum albumin and peritoneal dialysis patients. Am. J. Kidney Dis., 1997, 30, 923.
126. Yeun J.Y. i wsp.: C-reactive protein predicts all-cause and cardiovascular mortality in hemodialysis patients. Am. J. Kidney Dis., 2000, 35, 469.
127. Young G.A. i wsp.: Nutritional assessment of continuous ambulatory peritoneal dialysis patients: An international study. Am. J. Kidney Dis., 1991, 17, 462.
128. Zimmermann J. i wsp.: Inflammation enhances cardiovascular risk and mortality in hemodialysis patients. Kidney Int., 1999, 55, 648.
129. Zoccali C. i wsp.: Inflammation is associated with carotid atherosclerosis in dialysis patients. J. Hypertens., 2000, 18, 1207.
130. Zoccali C. i wsp.: Asymetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J. Am. Soc. Nephrol., 2002, 13, 490.
131. Zoccali C.: Endothelial damage, asymmetric dimethylarginine and cardiovascular risk in end-stage renal disease. Blood Purif., 2002, 20, 469.